11 Stocks That Will Bounce Back According to Analysts

Page 10 of 10

1. Vaxcyte, Inc. (NASDAQ:PCVX)

Year-to-Date Performance: -58.85%

Average Price Target Upside Potential According to Analysts: 304.03%

Number of Hedge Fund Holders: 50

Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage vaccine innovation that engineers, optimizes, and manufactures superior, high-fidelity vaccines. The company develops vaccines to prevent or treat bacterial infections like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Vaxcyte, Inc. (NASDAQ:PCVX) is one of the top stocks that will bounce back according to analysts.

On April 22, Cantor Fitzgerald initiated coverage of Vaxcyte, Inc. (NASDAQ:PCVX) with an “Overweight” rating after the company showcased promising VAX-31 pneumococcal conjugate vaccine (PCV) data in adults last fall. Despite the fact that Vaxcyte, Inc. (NASDAQ:PCVX) is facing challenges, like mixed results from its VAX-24 pediatric vaccine and shifts in US vaccine policy, Cantor Fitzgerald still is optimistic about the company’s long-term prospects. The firm’s analysis noted that the company’s programs are still years away from regulatory review. The adult VAX-31 is expected in 2027 while the pediatric strategy is expected in 2029. Cantor Fitzgerald suggests that by the time the company’s products come under review, the current leadership and policy environment could change and help the company’s trajectory. Vaxcyte, Inc. (NASDAQ:PCVX) has a strong position in the pneumococcal conjugate vaccine market, which is valued at over $8 billion, thanks to strong data from the adult VAX-31 trials. Additionally, Cantor Fitzgerald pointed out that the company has two ways to move forward with its pediatric vaccines with VAX-31 and a dose-optimized VAX-24. The firm’s commentary suggests that the stock’s current low price and market capitalization could bounce back if there are changes in the Health and Human Services (HHS), Food and Drug Administration (FDA), or Centers for Disease Control and Prevention (CDC) leadership and vaccine policy.

Overall, PCVX ranks first among the 11 stocks that will bounce back according to analysts. While we acknowledge the potential of these stocks, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than PCVX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 10 of 10